![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Dolutegravir Pharmacokinetics in
HIV-Infected Pregnant and Postpartum Women
|
|
|
Reported by Jules Levin
CROI 2016 Feb 22-24 Boston
Nikki Mulligan1, Brookie M. Best1, Edmund V. Capparelli1, Alice Stek2, Emily Barr3, Elizabeth Smith4, Nahida Chakhtoura5, Jiajia Wang6,
Sandra Burchett7, Mark Mirochnick8 on behalf of the IMPAACT 1026s Protocol Team
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, CA, US1, University of Southern California School of Medicine, Los Angeles, CA, US2, University of Colorado, Children's Hospital Colorado, Aurora, CO3,
Maternal, Adolescent, and Pediatric Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD4, Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD), Bethesda, MD5, Harvard T.H. Chan School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, USA6, Children's Hospital Boston, Boston, MA, US7, Boston University School of Medicine, Boston, MA, US8
![CROI1](../images/030816/030816-4/CROI1.gif)
![CROI2](../images/030816/030816-4/CROI2.gif)
![CROI3](../images/030816/030816-4/CROI3.gif)
![CROI4](../images/030816/030816-4/CROI4.gif)
![CROI5](../images/030816/030816-4/CROI5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|